

1614 #5
PATENT

MAR 06 2002

RECEIVED

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: J. Rahal Examiner: Unassigned
Serial No.: 09/935,966 Group Art Unit: 1614
Filed: August 23, 2001 Docket No.: 13099
For: Methods for Treating West Nile Virus

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, New York 10022

Dated: February 15, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit the following disclosures in accordance with the provisions of 37 CFR 1.97 and 1.98.

I. NON PATENT PUBLICATIONS

Hirsch et al., Nucleoside derivatives and interferons as antiviral agents, *Current Clinical Topics in Infectious Disease.*, Vol. 3:30-53 (1981).

Roberts et al., Phase I Clinical Studies of Ribavirin in High Risk Patients for the Acquired Immunodeficiency Syndrome, *Academic. Press* p. 95-112.

Holmes et al., Lassa Fever in the United States, *The New England Journal of Medicine*, pp. 1120-1123 (1990).

Odelola, Herbert, Antiviral Activity of Virazole on Replication of Viruses Isolated in Nigeria, *Virology*, pp. 334-335 (1977).

Certificate of Mailing Under 37 C.F.R. 1.8

I hereby declare that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C.

Date: 2/15/02 Name: J. Colwell

Certificate of Mailing Under 37 C.F.R. 1.8

I hereby declare that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C.

Date: _____

Update: West Nile Virus Encephalitis - New York, 1999, MMWR 48:944-955

Guidelines for Surveillance, Prevention, and Control of West Nile Virus Infection - United States, MMWR, 49:2 p. 25-28 (2000).

Update: West Nile Virus Activity-Northeastern United States, MMWR, 49:31 p.714-718 (2000).

Human West Nile Virus Surveillance-Connecticut, New Jersey, and New York, MMWR, 50:14 p. 265-268 (2000).

Laskin et al., Ribavirin Disposition in High Risk Patients for Acquired Immunodeficiency Syndrome, *Clinical Pharmacology And Therapeutics*, Vol.41, No. 5 pp.546-555 (1987).

Roberts et al., Ribavirin Pharmacodynamics in High-Risk Patients for Acquired Immunodeficiency Syndrome, *Clinical Pharmacology and Therapeutics*, Vol. 42, No. 4 pp.365-373 (1987).

Hosoya et al., High-Dose Intravenous Ribavirin Therapy for Subacute Sclerosing Panencephalitis, *Antimicrobial Agents and Chemotherapy*, Vol. 45, No.3 pp.943-945 (2001).

Briese et al., Testing for West Nile Virus, *The Lancet*, Vol. 356:1110 (2000).

Wang et al., Effect of Dosing Schedule on Pharmacokinetics of Alpha Interferon and Anti-Alpha Interferon Neutralizing Antibody in Mice, *Chronopharmacology of IFN- α* , Vol. 45:176-180 (2001).

Barry et al., Arenavirus Infection-Connecticut, *MMWR*, Vol. 43 No. 34 pp.635-636 (1994).

Forni et al., Severe Measles Pneumonitis in Adults: Evaluation of Clinical Characteristics and Therapy with Intravenous Ribavirin, *Clinical Infectious Diseases*, Vo. 19:454-462 (1994).

Hoch et al., Crimean Congo-Haemorrhagic Fever treated with oral ribavirin, *The Lancet*, Vol.346:472-476 (1995).

Barry et al., Brief Report: Treatment of a Laboratory-Acquired Sabia Virus Infection, *The New England Journal of Medicine*, Vol. 333:294-318 (1995).

Merigan, Thomas C., Interferon-The First Quarter Century, *JAMA*, Vol. 248 No. 19 pp.2513-2516 (1982),

Hayden, Fred, Basic Principles in the Diagnosis and Management of Infectious Diseases, Chapter 36 pp.474-479 (2000).

Smith et al., Distribution of alpha interferon in serum and cerebrospinal fluid after systematic administration, *Clin. Pharm. Ther.*, 37(1):85-88 (1985).

Centers for Disease Control and Prevention. Update: West Nile Virus Activity-Northeastern U.S., *MMWR*, Vol. 284 No. 10 1236-1238 (2000).

Centers for Disease Control and Prevention. Surveillance for West Nile Virus in Overwintering Mosquitoes -New York, Vol. 283 No. 18 pp.2380-2382 (2000).

Centers for Disease Control and Prevention. Update: West Nile Virus Activity-Northeastern United States, Vol. 284 No. 13 pp.1643-1644 (2000).

Centers for Disease Control and Prevention. Update: West Nile Virus Activity-Eastern U.S., Vol. 284 No. 24 pp.3119-3120 (2000).

Briese et al., Detection of West Nile virus sequences in cerebrospinal fluid, *The Lancet*, Vol. 355:1614-1616 (2000).

Briese et al., Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis, *The Lancet*, Vol. 354:1261-1262 (1999).

Kesson et al., Progressive Vaccinia Treated with Ribavirin and Vaccinia Immune Globulin, *Clinical Infectious Disease*, Vol.25:911-914 (1997).

Ljungman et al., Oral Ribavirin for Prevention of Severe Liver Disease Caused by Hepatitis C Virus During Allogeneic Bone Marrow Transplantation, *Clinical Infectious Disease*, Vol. 23:167-169 (1996).

Japour et al., A Phase-I Study of the Safety, Pharmacokinetics, and Antiviral Activity of Combination Didanosine and Ribavirin in Patients with HIV-1 Disease, *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, 13:235-246 (1996).

Huggins et al., Prospective, Double-Blind, Concurrent, Placebo-Controlled Clinical Trial of Intravenous Ribavirin Therapy of Hemorrhagic Fever with Renal Syndrome, *The Journal of Infectious Disease*, Vol.164:1119-1127 (1991).

Paul Glue, M.D., The Clinical Pharmacology of Ribavirin, *Seminars in Liver Disease*, 19:17-24 (1999).

N. Raphael Shulman, Assessment of Hematologic Effects of Ribavirin in Humans, *Academic Press.*, 94:29251-29264 (1984).

Centers for Disease Control and Prevention. West Nile Virus Activity-New York and New Jersey, Vol. 284 No. 7 pp.823-824 (2000).

Sidwell, R.W. et al., Ribavirin: An antiviral Agent, *Pharmacol. Ther.*, Vol.6 pp.2928529308, (1979).

Phochoda et al., Hantavirus-Associated Acute Respiratory Failure, *The New England Journal of Medicine*, pp.1744 (1993).

Centers for Disease Control and Prevention. Guidelines for Surveillance, Prevention, and Control of West Nile Virus Infection-U.S. vol. 49 No. 2 pp.25-28 (2000).

Holmes et al., Lassa Fever in the United States, *The New England Journal of Medicine*, 323:1120-1123 (1990).

Cardiovascular Infection by Chlamydia pneumonia Is Not Related to Apolipoprotein E Genotype, *Clinic of Infectious Disease* 2000;31:1515-1516.

Ishii et al., Effective Ribavirin Concentration in Hamster Brains for Antiviral Chemotherapy for Subacute Sclerosing Panencephalitis, *Antimicrobial Agents and Chemotherapy*, Vol. 40 No. 1 pp.241-243 (1996).

Sidwell, R.W., Ribavirin: In Vitro Antiviral Activity, *Academ. Press.*, Vol.94 pp.29265-29284 (1980).

Maslo et al., Ribavirin Therapy for Adenovirus Pneumonia in an AIDS Patient, *Amer. Journal Respir. Crit. Care Med.*, Vol. 156:1263-1264 (1997).

Lewinsohn et al., Phase I Study of Intravenous Ribavirin Treatment of Respiratory Syncytial Virus Pneumonia after Marrow Transplantation, *Antimicrobial Agents and Chemotherapy*, Vol. 40 No. 11 p.2555-2557 (1996).

CID: Reassessment of the Indications for Ribavirin Therapy in Respiratory Syncytial Virus Infections, *Pediatrics* Vol. 97 No. 1 pp. 137-140 (1996).

Bisceglie et al., Ribavirin as Therapy for Chronic Hepatitis C, *American College of Physicians*, Vol. 123 No. 12 p.897-902 (1995).

The Ribavirin ARC Study Group, Multicenter Clinical Trial of Oral Ribavirin in Symptomatic HIV-Infected Patients, *Journal of Acquired Immune Deficiency Syndrome*, Vol. 6 No. 1 pp.32-41 (1993).

Going et al., Ribavirin for Syncytial Giant Cell Hepatitis, *The Lancet*, Vol. 341 p. 640 (1993).

Isaacs, D., Ribavirin, *Pediatrics*, Vol. 79 No. 2 pp.289-291 (1987).

Prows, C.A., Ribavirin's Risks in Reproduction-How Great Are They?, *MCN*, Vol. 14:400-404 (1989).

Centers for Disease Control and Prevention. Human West Nile Virus Surveillance-Connecticut, New Jersey, and New York, Vol.285 No. 17 pp.2188-2190 (2001).

Canonico et al., Effects of Ribavirin on Red Blood Cells, *Toxicology and Applied Pharmacology*, Vol. 74 p.155-162 (1984).

Lanciotti, et al., Origin of the West Nile Virus Responsible for an Outbreak of Encephalitis in the Northeastern United States, *Science*, Vol. 286 pp.2333-2338 (1999).

Jia et al., Genetic analysis of West Nile New York 1999 encephalitis virus, *The Lancet*, Vol. 354 p.1971-1972 (1999).

Monath et al., Flaviviruses, *Clinical Virology*, Vol.49:1133-1140.

Bisceglie, A.M., Hepatitis C, *The Lancet*, Vol. 351 p.351-356 (1998).

Hubalek et al., West Nile Fever-a Reemerging Mosquito-Borne Viral Disease in Europe, *Emerging Infectious Diseases*, Vol. 5 No. 5 pp.643-650 (1999).

The City of New York Department of Health, Alert: Preliminary Results from the October 1999 Serosurvey for West Nile Virus in Northern Queens, (2000).

Update: West Nile Virus Encephalitis-New York, 1999, *MMWR*, Vol. 48 No. 41 pp.944-947 (1999).

Quagliarello, V., Emergence of West Nile Virus Encephalitis in the New York Metropolitan Area, *Clinical Infectious Disease* Vol. 2 pp.325-326 (2000).

Chen, David W., Lives that have been changed forever from after effects of a mosquito bite, *The New York Times*, pB1, August 19, 2000.

Klein et al., West Nile Virus in Nassau County, New York: The Long Island Experience, *Infectious Disease in Clinical Practice*, Vol. 9 No. 7 pp.303-308 (1999).

Shieh et al., The Role of Pathology in an Investigation of an Outbreak of West Nile Encephalitis in New York, *Emerging Infectious Diseases*, Vol. 6 No. 4 pp.370-372 (2000).

Sampson BA, The pathology of human West Nile Virus infection, *Hum Pathol*, Vol. 31(5) pp.527-531 (2000).

Nichter et al., Rhombencephalitis caused by West Nile fever virus, *Neurology*, July (1 of 2) 2000 p.153.

Asnis et al., The West Nile Virus Outbreak of 1999 in New York: The Flushing Hospital Experience, *Clinical Infectious Diseases*, 30:413-418 (2000).

Ahmed et al., Guillain-Barre syndrome: An unusual presentation of West Nile virus infection, *Neurology*, pp.144-146 (2000).

Silak et al., West Nile Viral Encephalitis in an HIV-Positive Woman in New York, *The New England Journal of Medicine*, Vol. 342 No. 1 pp.59-60 (2000).

Tsai et al., West Nile Encephalitis epidemic in southeastern Romania, *The Lancet*, Vol. 352 pp. 767-771 (1998).

Han et al., Risk Factors for West Nile Virus Infection and Meningoencephalitis, Romania, 1996, *The Journal of Infectious Diseases*, Vol. 179 pp.230-233 (1999).

Glue, Paul, The Clinical Pharmacology of Ribavirin, *Seminars in Liver Disease*, Vol. 19 pp.17-24 (1999).

Anderson et al., Isolation of West Nile Virus from Mosquitoes, Crows, and a Cooper's Hawk in Connecticut, *Science*, Vol. 286 pp. 2331-2333 (1999).

McCormick et al., Effective Therapy with Ribavirin, *The New England Journal of Medicine*, Vol. 314 No. 1 pp.20-26 (1998).

Jordan et al., Ribavirin Inhibits West Nile Virus Replication and Cytopathic Effect in Neural Cells, *The Journal of Infectious Diseases*, Vol. 182 pp.1214-1217 (2000).

Forni, et al., Severe Measles Pneumonitis in Adults: Evaluation of Clinical Characteristics and Therapy with Intravenous Ribavirin, *Clinical Infectious Diseases*, Vol. 19 pp.454-462 (1994).

Jacobsen, et al., Psychological Reactions of Individuals at Risk for AIDS During an Experimental Drug Trial, *Psychosomatics*, Vol. 29 No. 2 (1988).

Roberts et al., A Phase I Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients, *The Journal of Infectious Diseases*, Vol. 162 pp.638-642 (1990).

The Ribavirin ARC Study Group, Multicenter Clinical Trial of Oral Ribavirin in Symptomatic HIV-Infected Patients, *Journal of Acquired Immune Deficiency Syndromes*, Vol. 6 pp.32-41 (1993).

Budsworth et al., Ribavirin: A Role in HIV Infection?, *Journal of Acquired Immune Deficiency Syndromes*, Vol. 3 pp. 893-895 (1990).

Budsworth et al., Letters to the Editor, *Journal of Acquired Immune Deficiency Syndromes*, Vol. 3 pp.1017-1021 (1990).

Roberts et al., A Multicenter Clinical Trial of Oral Ribavirin in HIV-Infected Patients with Lymphadenopathy, *Journal of Acquired Immune Deficiency Syndromes*, Vol. 3 pp.884-892 (1990).

MMWR Update: West Nile Virus Isolated from Mosquitoes - New York 2000, Vol. 49 No. 10.

MMWR Update: Surveillance for West Nile Virus in Overwintering Mosquitoes - New York 2000, Vol. 49, No. 9 p.178-179.

Khakoo, S. *J. Clin Pharmacol*, Vol. 46, p.563-570.

Wall Street Journal, ICN Drug is Found Useful in Treating Hepatitis C, May. 3, 1991.

Roberts, Richard, Abstract Form: In Vitro Activity of Ribavirin in Acute and Cocultivated HIV Infection of Human Peripheral Blood Mononuclear Cells, *International Conference on Aids*, Montreal June 4-9 1989.

Reuters Information Service, Inc., ICN Says Ribavirin in Study Encouraging, Chicago-October 1, 1993.

Hepatitis C Virus, *Hepatitis Viruses* Chapter 62 p.533

Antiviral Activity of Interferons, *Interferons* p.393-410 chapter 16.

Arthropod-Borne Group B Virus Infections of Man, *West Nile Fever* p.321-324.

The items listed above are identified on Form PTO 1449, which is submitted with this statement. A copy of each of the items identified above is also submitted with this statement.

The attorneys for the Applicant takes no position on whether or not any item cited above and listed on Form PTO 1449 constitutes prior art against the subject application under any particular provision of Title 35 of the United States Code.

If a fee is deemed necessary, please charge any payment, or credit any overpayment, to deposit account no. 11-0171.

Respectfully submitted,



William D. Schmidt
Registration No.: 39,492
Attorney for Applicant

Kalow & Springut LLP
(212) 813-1600